Universität zu Köln

Journal Article

Abdulla, D. S. Y., Nogova, L., Riedel, R., Scheftler, M., Fischer, R. N., Michels, S., Heydt, C., Ihle, M. A., Fassunke, J., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2018). NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers. Oncol. Res. Treat., 41. S. 293 - 294. BASEL: KARGER. ISSN 2296-5262

Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Ceccon, G. S., Werner, J., Ruge, M., I, Goldbrunner, R., Celik, E., Baues, C., Deckert, M., Brunn, A., Buttner, R., Golla, H., Nogova, L., Schlamann, M., Kabbasch, C., Ruess, D., Hampl, J., Wollring, M., Bauer, E. K., Tscherpel, C., Fink, G. R., Langen, K. and Galldiks, N. (2022). Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors. Neuro-Oncology, 24. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Cernak, M. and Nogova, L. (2016). Current antiangiogenic agents in oncology and ophthalmology. Neoplasma, 63 (1). S. 10 - 18. BRATISLAVA: AEPRESS SRO. ISSN 1338-4317

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann. Oncol., 33 (8). S. S1386 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M. and Wolf, J. (2018). Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations. Oncol. Res. Treat., 41. S. 250 - 251. BASEL: KARGER. ISSN 2296-5262

Koenig, K., Peifer, M., Bos, M., Nogova, L., Merkelbach-Bruse, S., Stamm, K., Henkel, T., Thomas, R., Wolf, J., Buettner, R. and Heukamp, L. (2014). High throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathological routine diagnostics for a regional health care provider network. Oncol. Res. Treat., 37. S. 31 - 33. BASEL: KARGER. ISSN 2296-5262

Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Kron, F., Kostenko, A., Scheffler, M., Mueller, D., Glossmann, J. -P., Fischer, R., Michels, S., Nogova, L., Hallek, M., Zander, T. and Wolf, J. (2017). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer, 108. S. 134 - 140. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Meissner, A., Gutsche, R., Galldiks, N., Kocher, M., Junger, S., Eich, M., Nogova, L., Schmidt, N., Ruge, M., Goldbrunner, R., Proescholdt, M., Grau, S. and Lohmann, P. (2022). RADIOMICS FOR THE NON-INVASIVE ASSESSMENT OF THE PDL-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES. Neuro-Oncology, 24. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Michels, S., Brandes, V, Thurat, M., Nogova, L., Scheffler, M., Fischer, R., Merkelbach-Bruse, S., Hellmich, M., Buettner, R. and Wolf, J. (2016). EATON: An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy - a trial in preparation. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Michels, S., Plenker, D., Wagener, S., Scheffler, M., Nogova, L., Abdulla, D., Riedel, R., Bunck, A., Merkelbach-Bruse, S., Buettner, R., Sos, M. and Wolf, J. (2017). Loss of ROS1 G2032R resistance mutation upon chemotherapy treatment enables successful crizotinib rechallenge in a ROS1-rearranged NSCLC patient. Oncol. Res. Treat., 40. S. 232 - 233. BASEL: KARGER. ISSN 2296-5262

Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J. (2017). Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center. Oncol. Res. Treat., 40. S. 137 - 139. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R. and Wolf, J. (2020). FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Oncol. Res. Treat., 43 (SUPPL 4). S. 146 - 148. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R. and Wolf, J. (2018). FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress). Oncol. Res. Treat., 41. S. 294 - 295. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Mattonet, C., Gardizi, M., Scheffler, M., Bos, M., Woempner, C., Toepelt, K., Heukamp, L., Suleiman, A., Frechen, S., Soergel, F., Fuhr, U., Schnell, R., Katay, I., Behringer, D., Geist, T., Kaminski, B., Eichstaedt, M., Tummes, D., Buettner, R. and Wolf, J. (2014). SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Riedel, R., Michels, S., Heydt, C., Nogova, L., Fischer, R. N., Abdulla, D. S. Y., Scheffler, M., Merkelbach-Bruse, S., Kobe, C., Schaefer, S., Buettner, R. and Wolf, J. (2018). Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression. Oncol. Res. Treat., 41. S. 295 - 297. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Plenker, D., Michels, S., Nogova, L., Abdulla, D., Scheffler, M., Fischer, R., Brandes, V., Heukamp, L. C., Scheel, A. H., Buettner, R., Sos, M. L. and Wolf, J. (2017). KIF5B-MET fusion genes are novel targets in NSCLC and show sensitivity to MET inhibition with crizotinib. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Ihle, M. A., Merkelbach-Bruse, S., Michels, S., Nogova, L., Kron, A., Fischer, R., Serke, M., Ko, Y. -D., Gerigk, U., Schulte, W., Sebastian, M., Riedel, R., Holzem, A., Kambartel, K. -O., Buettner, R. and Wolf, J. (2017). Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Nogova, L., Michels, S., Fischer, R. N., Riedel, R., Woempner, C., Holzem, A., Thurat, M. and Wolf, J. (2018). Pharmacokinetics of nintedanib in combination with everolimus in patients with solid tumors - Results from the phase I BARIS trial. Oncol. Res. Treat., 41. S. 309 - 310. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Nogova, L., Papachristou, I., Persigehl, T., Dietlein, F., Zander, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 131 - 132. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Nogova, L., Michels, S., Woempner, C., Persigehl, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined nintedanib and everolimus in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 155 - 156. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Schuler, M., Cassier, P., Penel, N., Cathomas, R., Richly, H., Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Gruellich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P. and Joerger, M. (2018). Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway. Oncol. Res. Treat., 41. S. 321 - 322. BASEL: KARGER. ISSN 2296-5262

Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B. C., Sayehli, C. M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P. and Joerger, M. (2017). Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R. and Wolf, J. (2020). Small Cell Lung Cancer - Filling the gap between science and patients. Oncol. Res. Treat., 43 (SUPPL 4). S. 154 - 155. BASEL: KARGER. ISSN 2296-5262